natgillin/translations-raw huggingface dataset:
No relevant effects were seen with dolutegravir on the QTc interval, with doses exceeding the clinical dose by approximately three fold. 
Nisu primijećeni značajni učinci dolutegravira na QTc interval pri primjeni doza približno trostruko većih od kliničke doze.
It is not known whether the ingredients of Juluca can pass into your breast milk. 
Nije poznato mogu li sastojci lijeka Juluca prijeći u majčino mlijeko.
Selected established and theoretical interactions between dolutegravir, rilpivirine and co-administered medicinal products are listed in Table 1. 
Odabrane potvrđene i teorijske interakcije između dolutegravira, rilpivirina i istodobno primijenjenih lijekova navedene su u Tablici 1.
Dolutegravir is also a substrate of UGT1A3, UGT1A9, cytochrome P450 (CYP)3A4, Pglycoprotein (P-gp), and breast cancer resistance protein (BCRP); therefore medicinal products that induce those enzymes may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir (see Table 1). 
Dolutegravir je i supstrat za UGT1A3, UGT1A9, citokrom P450 (CYP)3A4, P-glikoprotein (P-gp) i protein rezistencije raka dojke (engl. breast cancer resistance protein, BCRP); stoga lijekovi koji induciraju navedene enzime mogu smanjiti koncentracije dolutegravira u plazmi i tako oslabiti terapijski učinak dolutegravira (vidjeti Tablicu 1).
common decreased appetite increased triglycerides (fasted) Psychiatric disorders very common insomnia common abnormal dreams depression sleep disorders depressed mood anxiety uncommon suicidal ideation or suicide attempt (particularly in patients with a pre-existing history of depression or psychiatric illness) 
Psihijatrijski poremećaji vrlo često nesanica često neuobičajeni snovi depresija poremećaji spavanja depresivno raspoloženje anksioznost manje često suicidalne misli ili pokušaj suicida (osobito u bolesnika s depresijom ili psihijatrijskom bolešću u anamnezi)
Very common side effects that may show up in blood tests are: 
Vrlo česte nuspojave koje se mogu vidjeti u nalazima krvnih pretraga:
In contrast, starting passage with mutants with mutation Q148H (FC 1), a variety of raltegravir associated secondary mutations accumulated with a consequent increase of FC to values >10. 
Nasuprot tome, ako je pasaža započela s mutantima koji su imali mutaciju Q148H (FC 1), akumulirao se niz različitih sekundarnih mutacija povezanih s primjenom raltegravira, što je za posljedicu imalo porast FC-a na vrijednosti > 10.
Animal studies with dolutegravir or rilpivirine do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). 
Ispitivanja dolutegravira ili rilpivirina na životinjama ne ukazuju na izravne ni neizravne štetne učinke u smislu reproduktivne toksičnosti (vidjeti dio 5.3).
(induction of CYP3A due to high rilpivirine dose in the study). 
(Indukcija CYP3A zbog visoke doze rilpivirina u ispitivanju)
Physicians should refer to current treatment guidelines for the management of HIV infection in patients co-infected with hepatitis B virus. 
Liječnici trebaju pogledati trenutne smjernice za liječenje HIV infekcije u bolesnika s istodobnom infekcijom virusom hepatitisa B.
Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor (see section 5.1). 
Juluca je indicirana za liječenje infekcije virusom humane imunodeficijencije tipa 1 (HIV-1) u odraslih osoba u kojih je stabilnim antiretrovirusnim režimom postignuta virološka supresija (HIV-1 RNK < 50 kopija/ml) u trajanju od najmanje šest mjeseci i koje u anamnezi nemaju virološki neuspjeh ni poznatu ili suspektnu rezistenciju na bilo koji nenukleozidni inhibitor reverzne transkriptaze ili inhibitor integraze (vidjeti dio 5.1).
If the patient misses a dose of Juluca, the patient should take Juluca with a meal as soon as possible, providing the next dose is not due within 12 hours. 
Ako bolesnik propusti dozu lijeka Juluca, treba je uzeti uz obrok što je prije moguće, pod uvjetom da do sljedeće doze nije preostalo manje od 12 sati.
The frequency category of rare was estimated based on postmarketing reports. 
Kategorija učestalosti ‘rijetko' procijenjena je na temelju prijava nakon stavljanja lijeka u promet.
Lower exposures of dolutegravir or rilpivirine were observed when taken once daily, in combination with a background regimen, during pregnancy. 
Primijećena je manja izloženost dolutegraviru ili rilpivirinu kod primjene jedanput na dan tijekom trudnoće, u kombinaciji s osnovnim režimom.
Juluca contains dolutegravir and rilpivirine, therefore any interactions identified with these active substances are relevant to Juluca. 
Juluca sadrži dolutegravir i rilpivirin, pa su sve interakcije utvrđene kod primjene tih djelatnih tvari relevantne i za lijek Juluca.
Pregnancy and postpartum 
Trudnoća i razdoblje nakon poroda
Dolutegravir is rapidly absorbed following oral administration, with median Tmax at 2 to 3 hours post dose for tablet formulation. 
Dolutegravir se nakon peroralne primjene brzo apsorbira, pri čemu je medijan Tmax 2 do 3 sata nakon primjene doze u obliku tablete.
The combination of Juluca and artemether/lumefantrine should be used with caution. 
Kombinaciju lijeka Juluca i artemetera/lumefantrina treba primjenjivati uz oprez.
INFORMATION IN BRAILLE juluca 
16. PODACI NA BRAILLEOVOM PISMU juluca
• medicines called H2 receptor antagonists (for example cimetidine, famotidine, nizatidine, ranitidine) to treat stomach or intestinal ulcers or used to relieve heartburn due to acid reflux). 
• lijekove koji se zovu antagonisti H2-receptora (npr. cimetidin, famotidin, nizatidin, ranitidin), a koriste se za liječenje želučanih ili crijevnih vrijedova ili ublažavanje žgaravice uzrokovane refluksom kiseline.
Animal studies indicate no clinically relevant effects on male or female fertility (see section 5.3). 
Ispitivanja na životinjama nisu pokazala klinički značajne učinke na plodnost mužjaka ili ženki (vidjeti dio 5.3).
Rilpivirine ↔* EE ↔ 
rilpivirin ↔* EE ↔
1 The interaction between dolutegravir and/or rilpivirine and the medicinal product was evaluated in a clinical study. 
Interakcija između dolutegravira i/ili rilpivirina i tih lijekova procjenjivala se u kliničkom ispitivanju.
The effect of severe hepatic impairment (Child-Pugh score C) on the pharmacokinetics of dolutegravir or rilpivirine has not been studied, therefore Juluca is not recommended in these patients. 
Učinak teškog oštećenja jetrene funkcije (Child-Pugh stadij C) na farmakokinetiku dolutegravira ili rilpivirina nije se ispitivao, pa se primjena lijeka Juluca ne preporučuje u tih bolesnika.
Rilpivirine also demonstrated antiviral activity against a broad panel of HIV-1 group M (clades A, B, C, D, F, G, H) primary isolates with IC50 values ranging from 0.07 to 1.01 nM and group O primary isolates with EC50 values ranging from 2.88 to 8.45 nM. 
Rilpivirin je pokazao antivirusnu aktivnost i protiv široke palete primarnih izolata HIV-1 iz skupine M (podtipovi A, B, C, D, F, G, H), uz vrijednosti IC50 u rasponu od 0,07 do 1,01 nM, te primarnih izolata iz skupine O, uz vrijednosti EC50 u rasponu od 2,88 do 8,45 nM.
Systemic exposure to rilpivirine was generally lower in HIV-1 infected patients than in healthy subjects. 
Sistemska izloženost rilpivirinu u načelu je bila manja u bolesnika s HIV-1 infekcijom nego u zdravih ispitanika.
Dolutegravir belongs to a group of anti-retroviral medicines called integrase inhibitors (INIs), and rilpivirine belongs to a group of anti-retroviral medicines called nonnucleoside reverse transcriptase inhibitors (NNRTIs). 
Dolutegravir pripada skupini antiretrovirusnih lijekova koji se nazivaju inhibitori integraze, a rilpivirin pripada skupini antiretrovirusnih lijekova koji se zovu nenukleozidni inhibitori reverzne transkriptaze (engl. non-nucleoside reverse transcriptase inhibitors, NNRTI).
Rilpivirine 25 mg once daily is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. 
Nije vjerojatno da će rilpivirin u dozi od 25 mg jedanput na dan imati klinički značajnog učinka na izloženost lijekovima koje metaboliziraju CYP enzimi.
The single amino acid substitutions associated with a loss of susceptibility to rilpivirine were: K101P, Y181I and Y181V. 
Pojedinačne aminokiselinske supstitucije povezane s gubitkom osjetljivosti na rilpivirin bile su K101P, Y181I i Y181V.
In 100% human serum, the dolutegravir mean protein fold shift was 75 fold, resulting in protein adjusted IC90 of 0.064 µg/mL. 
U 100%-tnom ljudskom serumu srednja vrijednost promjene ekspresije proteina kod primjene dolutegravira iznosila je 75 puta, što je za posljedicu imalo vrijednost IC90 prilagođenu za proteine od 0,064 µg/ml.
300 mg once daily (+ 25 mg once daily rilpivirine) 
300 mg jedanput na dan (+ 25 mg rilpivirina jedanput na dan)
Effect of other medicinal products on the pharmacokinetics of dolutegravir and rilpivirine 
Učinci drugih lijekova na farmakokinetiku dolutegravira i rilpivirina
• increase in bilirubin (a test of liver function) in your blood. 
• povećanje vrijednosti bilirubina (kojim se određuje funkcija jetre) u krvi
Juluca must not be taken with some other medicines (see ‘Do not take Juluca' earlier in section 2). 
Juluca se ne smije se uzimati zajedno s određenim lijekovima (pogledajte odlomak ‘Nemojte uzimati lijek Juluca', naveden ranije u ovom dijelu).
In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development of resistance to the integrase class, or to the NRTI class was seen (n=876, follow-up of 48-96 weeks). 
U prethodno neliječenih bolesnika koji su u ispitivanjima faze IIb i faze III primali dolutegravir + 2 nukleozidna inhibitora reverzne transkriptaze (NRTI) nije primijećen razvoj rezistencije na skupinu inhibitora integraze ni na skupinu NRTI-ja (n=876, praćenje u trajanju od 48 - 96 tjedana).
Available toxicological data in animals has shown excretion of dolutegravir and rilpivirine in milk. 
Dostupni toksikološki podaci prikupljeni u životinja pokazuju da se dolutegravir i rilpivirin izlučuju u mlijeko.
** Non-inferiority of dolutegravir plus rilpivirine to CAR, in the proportion of subjects classified as virologic non-responders, was demonstrated using a non-inferiority margin of 4%. 
** Neinferiornost dolutegravira plus rilpivirina u odnosu na dotadašnji kombinirani antiretrovirusni režim među ispitanicima koje se smatralo bolesnicima bez virološkog odgovora dokazana je koristeći graničnu vrijednost neinferiornosti od 4%.
Virologic Outcomes of Randomized Treatment at Week 48 (Snapshot algorithm) 
Tablica 3: Virološki ishodi randomiziranog liječenja u 48. tjednu (algoritam za globalnu snimku distribuiranog sustava [engl. snapshot algoritam])
Juluca should not be co-administered at the same time as antacids. 
Juluca se ne smije primjenjivati istodobno s antacidima.
As dolutegravir and rilpivirine are highly bound to plasma proteins, it is unlikely that they will be significantly removed by haemodialysis or peritoneal dialysis (see section 4.2). 
Budući da se dolutegravir i rilpivirin u velikoj mjeri vežu za proteine u plazmi, nije vjerojatno da će se značajno ukloniti hemodijalizom ili peritonejskom dijalizom (vidjeti dio 4.2).
No mother to child transmission was identified. 
Nije utvrđen nijedan slučaj prijenosa infekcije s majke na dijete.
Keep this medicine out of the sight and reach of children. 
Kako čuvati lijek Juluca Lijek čuvajte izvan pogleda i dohvata djece.
Patients with hepatitis B or C 
Bolesnici s hepatitisom B ili C
White HDPE (high density polyethylene) bottles closed with polypropylene child-resistant closures, with a polyethylene faced induction heat seal liner. 
Bijele boce od polietilena visoke gustoće (HDPE) zatvorene polipropilenskim zatvaračima sigurnima za djecu i polietilenskom toplinski zavarenom zaštitnom folijom.
Rilpivirine exhibited activity against laboratory strains of wild-type HIV-1 in an acutely infected T-cell line with a median IC50 value for HIV-1/IIIB of 0.73 nM (0.27 ng/mL). 
Rilpivirin je pokazao aktivnost protiv laboratorijskih sojeva divljeg tipa HIV-1 u akutno zaraženoj T-staničnoj liniji, uz medijan vrijednosti IC50 za HIV-1/IIIB od 0,73 nM (0,27 ng/ml).
Renal elimination of rilpivirine is negligible. 
Eliminacija rilpivirina kroz bubrege je zanemariva.
The safety and efficacy of Juluca in pregnancy have not yet been established. 
Sigurnost i djelotvornost lijeka Juluca u trudnica još nisu ustanovljene.
No data are available in patients with severe hepatic impairment (Child-Pugh score C); therefore Juluca is not recommended in these patients (see section 5.2). 
Nema dostupnih podataka o bolesnicima s teškim oštećenjem jetrene funkcije (Child-Pugh stadij C), pa se u tih bolesnika ne preporučuje primjena lijeka Juluca (vidjeti dio 5.2).
The most severe adverse reaction, possibly related to the treatment with dolutegravir (from pooled from Phase IIb and Phase III clinical studies), seen in an individual patient, was a hypersensitivity reaction that included rash and severe liver effects (see section 4.4). 
Najteža nuspojava koja bi mogla biti povezana s liječenjem dolutegravirom (prema objedinjenim podacima iz kliničkih ispitivanja faze IIb i faze III), primijećena u samo jednog bolesnika, bila je reakcija preosjetljivosti koja je uključivala osip i teške učinke na jetru (vidjeti dio 4.4).
• increase in lipase (an enzyme involved in breaking down fats) 
• povećanje vrijednosti lipaze (enzima koji sudjeluje u razgradnji masnoća)
This patient's viral load was 1,059,771 copies/mL at the suspected virologic withdrawal visit and was <50 copies/mL at the withdrawal visit. 
Virusno opterećenje tog bolesnika bilo je 1 059 771 kopija/ml pri posjetu na kojem se posumnjalo na virološki neuspjeh te
Each film-coated tablet contains 52 mg lactose (as monohydrate). 
Jedna filmom obložena tableta sadrži 52 mg laktoze (u obliku hidrata).
If you take too many tablets of Juluca contact your doctor or pharmacist immediately. 
Ako uzmete previše Juluca tableta, odmah se obratite svom liječniku ili ljekarniku.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (MULTIPACKS ONLY - WITH BLUE BOX) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA (SAMO VIŠESTRUKA PAKIRANJA - S PLAVIM OKVIROM)
In vitro, dolutegravir was not a substrate of human OATP 1B1, OATP 1B3 or OCT 1. 
In vitro, dolutegravir nije bio supstrat ljudskih prijenosnika OATP1B1, OATP1B3 ni OCT1.
Medicinal products that induce or inhibit CYP3A may thus affect the clearance of rilpivirine (see section 5.2). 
Lijekovi koji induciraju ili inhibiraju CYP3A mogu stoga utjecati na klirens rilpivirina (vidjeti dio 5.2).
The effect of rilpivirine at the recommended dose of 25 mg once daily on the QTcF interval was evaluated in a randomised, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady-state. 
Učinak rilpivirina u preporučenoj dozi od 25 mg jedanput na dan na QTcF interval ocjenjivao se u randomiziranom, placebom i aktivnim lijekom (moksifloksacin 400 mg jedanput na dan) kontroliranom ukriženom ispitivanju provedenom u 60 zdravih odraslih osoba, u kojem je provedeno 13 mjerenja tijekom razdoblja od 24 sata u stanju dinamičke ravnoteže.
The mean IC50 for 3 HIV-2 isolates was 0.18 nM (range 0.09 
Srednja vrijednost IC50 za 3 izolata HIV-2 iznosila je 0,18 nM (raspon:
Subjects with hepatitis B co-infection or hepatitis C infection in need of anti-HCV therapy were excluded from studies with the dual combination of dolutegravir and rilpivirine. 
Ispitanici s istodobnom infekcijom virusom hepatitisa B ili ispitanici s infekcijom virusom hepatitisa C kojima je bila potrebna terapija za liječenje HCV infekcije nisu bili uključeni u ispitivanja dvojne kombinacije dolutegravira i rilpivirina.
Using strain NL432, integrase mutations E92Q (fold change [FC] 3) and G193E (FC 3) were selected. 
NL432, izdvojene su mutacije integraze E92Q (vrijednost promjene [engl. fold change, FC] 3) i
Rifabutin/ Rilpivirine1 300 mg once daily2 
rifabutin / rilpivirin1 300 mg jedanput na dan2
In reproductive toxicity studies in animals, dolutegravir was shown to cross the placenta. 
Ispitivanja reproduktivne toksičnosti na životinjama pokazala su da dolutegravir prolazi kroz placentu.
Juluca has not been studied in patients on dialysis. 
Juluca se nije ispitivala u bolesnika na dijalizi.
In vitro experiments indicate that rilpivirine primarily undergoes oxidative metabolism mediated by the CYP3A system. 
Eksperimenti in vitro ukazuju na to da rilpivirin prvenstveno podliježe oksidacijskom metabolizmu posredovanom enzimima sustava CYP3A.
Rilpivirine did not induce chromosomal damage in the in vivo micronucleus test in mice. 
Rilpivirin nije inducirao oštećenje kromosoma u mikronukleusnom testu in vivo u miševa.
If the next dose is due within 12 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. 
Ako je do sljedeće doze preostalo manje od 12 sati, bolesnik ne smije uzeti propuštenu dozu, nego samo nastaviti s primjenom prema uobičajenom rasporedu.
Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). 
Aktivnosti rilpivirina posredovana je nekompetitivnom inhibicijom reverzne transkriptaze (RT) virusa HIV-1.
25-O-desacetyl-rifabutin 
25-O-dezacetilrifabutin
Rilpivirine-resistant strains were selected in cell culture starting from wild type HIV-1 of different origins and clades as well as NNRTI-resistant HIV-1. 
Sojevi rezistentni na rilpivirin izdvojeni su u staničnoj kulturi, počevši od virusa HIV-1 divljeg tipa različitog podrijetla i podtipova te virusa HIV-1 rezistentnog na NNRTI.
(reduced absorption due to gastric pH increase). 
(Smanjena apsorpcija zbog povećanja želučane pH
Rilpivirine studies in animals have shown no evidence of relevant embryonic or foetal toxicity or an effect on reproductive function. 
Ispitivanja rilpivirina na životinjama nisu pokazala dokaze relevantne toksičnosti za zametak ili plod ni učinak na reproduktivnu funkciju.
Table 1: 
Tablicu 1).
Rilpivirine inhibits P-gp in vitro (IC50 is 9.2 μM). 
P-gp in vitro (IC50 iznosi 9,2 μM).
Rilpivirine is primarily metabolised by CYP3A. 
Rilpivirin se prvenstveno metabolizira posredstvom CYP3A.
The absolute bioavailability of dolutegravir or rilpivirine has not been established. 
Apsolutna bioraspoloživost dolutegravira ili rilpivirina nije ustanovljena.
Dolutegravir or rilpivirine did not change ethinyl estradiol and norelgestromin (dolutegravir) or norethindrone (rilpivirine) plasma concentrations to a clinically relevant extent. 
Dolutegravir i rilpivirin nisu promijenili plazmatske koncentracije etinilestradiola i norelgestromina (dolutegravir) ni noretindrona
Rilpivirine has tested negative in the absence and presence of a metabolic activation system in the in vitro Ames reverse mutation assay and the in vitro clastogenicity mouse lymphoma assay. 
Rezultati testiranja rilpivirina bili su negativni u odsutnosti i prisutnosti sustava metaboličke aktivacije u Amesovu testu reverzne mutacije in vitro i testu klastogenosti na mišjem limfomu in vitro.
Rilpivirine at the recommended dose of 25 mg once daily is not associated with a clinically relevant effect on QTc. 
Rilpivirin primijenjen u preporučenoj dozi od 25 mg jedanput na dan nije povezan s klinički značajnim učinkom na QTc interval.
Warnings and precautions Talk to your doctor or, pharmacist before taking Juluca. 
Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek Juluca.
Subjects were randomised 1:1 to continue their CAR or be switched to a two-drug regimen dolutegravir plus rilpivirine administered once daily. 
Ispitanici su bili randomizirani u omjeru 1:1 za nastavak liječenja dotadašnjim antiretrovirusnim režimom ili za prelazak na dvojni režim liječenja dolutegravirom plus rilpivirinom jedanput na dan.
Dolutegravir pharmacokinetics are similar between healthy and HIV-infected subjects. 
Farmakokinetika dolutegravira slična je u zdravih ispitanika i u onih s HIV infekcijom.
common increased bilirubin uncommon hepatitis rare acute hepatic failure** 
često povišene vrijednosti bilirubina manje često hepatitis rijetko akutno zatajenje jetre**
No efficacy and safety data are available for the combination of dolutegravir and rilpivirine in pregnancy. 
Nema dostupnih podataka o djelotvornosti i sigurnosti primjene kombinacije dolutegravira i rilpivirina u trudnoći.
Rilpivirine is an in vitro inhibitor of the transporter MATE-2K with an IC50 of < 2.7 nM. 
Rilpivirin je inhibitor prijenosnika MATE-2K in vitro, uz IC50 od < 2,7 nM.
Limited data are available regarding the use of dolutegravir during pregnancy. 
Dostupni su ograničeni podaci o primjeni dolutegravira tijekom trudnoće.
Metformin is eliminated renally and therefore it is of importance to monitor renal function when co-treated with Juluca. 
Metformin se izlučuje putem bubrega, stoga je važno nadzirati bubrežnu funkciju kada se primjenjuje istodobno s lijekom Juluca.
A study of the pharmacokinetics of dolutegravir was performed in subjects with severe renal impairment (CLcr <30 mL/min) and matched healthy controls. 
Ispitivanje farmakokinetike dolutegravira provedeno je u ispitanika s teškim oštećenjem bubrežne funkcije (CLcr < 30 ml/min) i farmakokinetika je odgovarala onoj u zdravih kontrolnih ispitanika.
In patients with prior failed therapies, but naïve to the integrase class (SAILING study), integrase inhibitor substitutions were observed in 4/354 patients (follow-up 48 weeks) treated with dolutegravir, which was given in combination with an investigator selected background regimen (BR). 
U bolesnika koji su neuspješno odgovorili na prethodne terapije, ali nisu primali lijekove iz skupine inhibitora integraze (ispitivanje SAILING), supstitucije povezane s rezistencijom na inhibitore integraze primijećene su u 4/354 bolesnika (praćenje od 48 tjedana) liječenih dolutegravirom, koji se primjenjivao u kombinaciji s osnovnim režimom liječenja po izboru ispitivača.
The pharmacokinetic properties of rilpivirine have been evaluated in adult healthy subjects and in adult antiretroviral treatment-naïve HIV-1 infected patients. 
Farmakokinetička svojstva rilpivirina ocjenjivala su se u zdravih odraslih ispitanika i u odraslih bolesnika s HIV-1 infekcijom koji se prethodno nisu liječili antiretroviroticima.
Therefore, use of Juluca during pregnancy is not recommended (see sections 4.4, 4.6, 5.1 and 5.2). 
Stoga se primjena lijeka Juluca tijekom trudnoće ne preporučuje (vidjeti dijelove 4.4, 4.6, 5.1 i 5.2).
Some medicines can affect how Juluca works, or make it more likely that you will have side effects. 
Neki lijekovi mogu utjecati na način djelovanja lijeka Juluca ili povećati vjerojatnost pojave nuspojava.
A reduction in the antiviral activity of rilpivirine was observed in the presence of 1 mg/mL alpha-1-acid glycoprotein, 45 mg/mL human serum albumin, and 50% human serum as demonstrated by median IC50 rates of 1.8, 39.2 and 18.5, respectively. 
U prisutnosti 1 mg/ml alfa-1-kiselog glikoproteina, 45 mg/ml ljudskog serumskog albumina i 50% ljudskog seruma opaženo je smanjenje antivirusne aktivnosti rilpivirina, što pokazuju medijani stopa IC50 od 1,8, 39,2 odnosno 18,5.
Liver problems including hepatitis B and/or C 
Jetrene tegobe, uključujući hepatitis B i/ili C
Dolutegravir activity was determined against a panel of 60 INI-resistant site-directed mutant HIV-1 viruses (28 with single substitutions and 32 with 2 or more substitutions). 
Virusni izolat s ciljanom mutagenezom rezistentan na inhibitore integraze Aktivnost dolutegravira određivala se protiv palete od 60 izolata HIV-1 s ciljanom mutagenezom rezistentnih na inhibitore integraze (28 izolata s jednom supstitucijom i 32 izolata s 2 ili više supstitucija).
• symptoms of infections and inflammation 
• simptome infekcija i upale